Lincoln Pharmaceuticals Limited (BOM:531633)

Lincoln Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	322.11	215.28	134.14	57.47	50.52	69.34
Short-Term Investments	2,446	106.47	85.77	77.83	116.57	113.82
Trading Asset Securities	-	2,085	1,737	1,389	913.26	968.06
Cash & Short-Term Investments	2,768	2,407	1,957	1,524	1,080	1,151
Cash Growth	19.35%	23.00%	28.38%	41.11%	-6.16%	21.81%
Accounts Receivable	1,644	1,614	1,664	1,618	1,363	1,159
Other Receivables	-	2.35	1.67	0.64	1.35	3.4
Receivables	2,485	2,437	2,027	1,922	1,604	1,490
Inventory	816.69	801.06	786.77	771.68	700.28	727.42
Prepaid Expenses	-	15.81	18.09	16.25	19.36	3.73
Other Current Assets	361.58	169.75	210.75	143.83	268.29	156.19
Total Current Assets	6,431	5,831	4,999	4,378	3,672	3,528
Property, Plant & Equipment	1,965	1,953	1,860	1,825	1,569	1,476
Long-Term Investments	0.03	1.18	0.03	0.04	0.03	0.03
Other Intangible Assets	10.51	9.2	4.4	3.26	2.95	3.83
Other Long-Term Assets	332.4	37.23	43.07	47.63	33.74	65.15
Total Assets	9,642	8,904	7,970	7,003	5,874	5,344

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	955.02	848.63	849.48	724.4	508.67	716.67
Accrued Expenses	-	25.18	20.42	90.06	82.92	70.14
Short-Term Debt	34.22	44.22	-	10.67	19.97	20.44
Current Income Taxes Payable	31.7	16.55	-	0.71	8.82	42.77
Other Current Liabilities	244.83	175.87	192.26	96.93	101.08	54.85
Total Current Liabilities	1,266	1,110	1,062	922.77	721.45	904.86
Long-Term Unearned Revenue	63.88	64.37	53.85	36.25	47.21	45.39
Pension & Post-Retirement Benefits	7.78	17.57	7.34	0.97	1.39	-
Long-Term Deferred Tax Liabilities	189.35	135.34	130.02	114.56	79.41	64.55
Total Liabilities	1,527	1,328	1,253	1,075	849.46	1,015

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	200.3	200.3	200.3	200.3	200.3	200.3
Additional Paid-In Capital	-	646.17	646.17	646.17	646.17	646.17
Retained Earnings	-	6,812	5,969	5,182	4,279	3,580
Comprehensive Income & Other	7,915	-82.4	-99.15	-100.06	-100.67	-97.7
Total Common Equity	8,115	7,576	6,717	5,928	5,025	4,329
Shareholders' Equity	8,115	7,576	6,717	5,928	5,025	4,329
Total Liabilities & Equity	9,642	8,904	7,970	7,003	5,874	5,344

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	34.22	44.22	-	10.67	19.97	20.44
Net Cash (Debt)	2,734	2,363	1,957	1,514	1,060	1,131
Net Cash Growth	17.91%	20.74%	29.28%	42.76%	-6.22%	20.31%
Net Cash Per Share	136.50	117.97	97.71	75.58	52.94	56.46
Filing Date Shares Outstanding	20.03	20.03	20.03	20.03	20.03	20.03
Total Common Shares Outstanding	20.03	20.03	20.03	20.03	20.03	20.03
Working Capital	5,165	4,720	3,937	3,455	2,951	2,624
Book Value Per Share	405.24	378.25	335.34	295.98	250.86	216.12
Tangible Book Value	8,105	7,567	6,712	5,925	5,022	4,325
Tangible Book Value Per Share	404.72	377.79	335.12	295.82	250.72	215.93
Land	-	204.98	200.24	200.24	187.36	186.32
Buildings	-	684.84	626.46	602.21	580.66	478.61
Machinery	-	1,828	1,675	1,548	1,192	1,031
Construction In Progress	-	52.28	44.7	34.83	67.14	160.54

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error